Latest news with #epidermolysisbullosa
Forbes
2 days ago
- Entertainment
- Forbes
Eddie Vedder Amplifies Fight Against Childrens Butterfly Disease
NEW YORK, NEW YORK - FEBRUARY 03: Eddie Vedder And The Earthlings perform at theBeacon Theatre on ... More February 03, 2022 in New York City. (Photo by) Pearl Jam's frontman turns his platform into a powerful force for epidermolysis bullosa research, just as breakthrough gene therapies offer unprecedented hope. Matter of Time, a documentary that follows Eddie and Jill Vedder and a passionate community uniting to cure a devastating disease, will have its world premiere to a sold-out audience at the 24th Tribeca Festival in New York on Thursday, June 12th. The film captures the electrifying energy of Vedder's solo concerts in Seattle, organized to raise funds for Epidermolysis Bullosa (EB) - a rare and debilitating genetic skin disorder that mostly affects children, causing fragile, blistering skin. When Pearl Jam's Eddie Vedder took the stage in Seattle in October 2023, he wasn't just performing for his devoted fanbase. The legendary musician was on a mission that extended far beyond entertainment—raising critical funds for epidermolysis bullosa (EB) research while documenting the journey in what would become the compelling documentary Matter of Time. All proceeds from these concerts went directly to EB Research Partnership (EBRP), the world's largest organization funding research for EB, with the ambitious goal of finding a cure by 2030. 'It's so special to be playing for a purpose, the purpose being this incredible mission,' Vedder told in a trailer for the upcoming film. His words capture a moment of convergence between celebrity advocacy and scientific breakthrough that couldn't be more timely. The Perfect Storm of Progress The Vedders' fundraising concerts come at a pivotal moment in the fight against EB, a devastating genetic condition that causes the skin to blister and tear at the slightest touch—earning it the heartbreaking nickname 'butterfly disease' because patients' skin is as fragile as a butterfly's wings. The timing is particularly significant given the recent wave of therapeutic breakthroughs that have transformed what was once considered an untreatable condition into one where hope is becoming reality. The disease affects approximately 1 in 50,000 births globally, with patients enduring a lifetime of painful wounds, restricted movement, and often shortened lifespans due to complications. For decades, treatment was limited to wound care and pain management. Today, that landscape is rapidly changing. Professor Jean Tang, Stanford Medicine Gene Therapy Breakthrough Reshapes Treatment Landscape The scientific community has achieved what many considered impossible just years ago. FDA approves Vyjuvek, a herpes-simplex virus type 1 vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa—marking the first approved topical gene therapy for this devastating condition. This groundbreaking treatment represents more than just medical progress; it embodies the same spirit of hope that the Vedders channels in advocacy. A gene therapy gel applied to the wounds of nine people - three of whom were children - with the blistering skin disease epidermolysis bullosa helped the wounds heal and remain healed for several months in clinical trials led by Stanford Medicine researchers. The therapy works by delivering the correct genetic code directly to affected skin areas, essentially teaching the body to produce the missing proteins that would normally hold skin layers together. For patients who have lived with chronic, painful wounds for decades, this represents nothing short of a miracle. DNA and Gene Therapy The Power of Purpose-Driven Advocacy Jill and Eddie Vedder co-founded EBRP with a group of families, with the sheer intent of curing this devastating disease, working tirelessly to raise awareness and drive resources toward groundbreaking research. Produced by Door Knocker Media in association with EB Research Partnership and the Vitalogy Foundation, Matter of Time blends powerful music with the poignant, real-life stories of patients, families, researchers, and thought leaders, revealing how determination and innovation are paving the way toward a cure. The film shows a community fiercely dedicated to ending EB, capturing the spirit, resilience, and grit needed to tackle this challenging but achievable mission The Vedders' approach to advocacy demonstrates how celebrity platforms can accelerate medical research in meaningful ways. Rather than simply writing a check, the musician has created a multimedia experience that educates audiences while generating substantial funding. The documentary Matter of Time showcases both the human stories behind EB and the cutting-edge research offering new hope. 'The goal is treatments. The goal is ultimately a cure,' Vedder says. 'It brings a sense of hope that feels like just a matter of time.' This sentiment perfectly captures the current moment in EB research, where multiple therapeutic approaches are showing remarkable promise. The musician's concerts weren't just fundraising events—they were awareness campaigns that brought a rare disease into the mainstream conversation. This type of advocacy has proven crucial for rare disease research, where limited patient populations often mean limited research funding and pharmaceutical interest. Multiple Pathways to Healing The field of EB treatment is experiencing what researchers call a 'therapeutic renaissance.' Beyond the FDA-approved topical gene therapy, several other approaches are showing promise: The Economic Impact of Breakthrough Therapies The development of EB treatments represents a significant economic opportunity within the rare disease pharmaceutical market. Gene therapies, while expensive to develop and initially costly to patients and healthcare systems, often prove cost-effective over time by preventing the chronic care needs that characterize rare diseases. For EB patients, traditional care involves constant wound dressing changes, pain management, nutritional support, and management of complications—costs that can exceed hundreds of thousands of dollars annually per patient. Curative or highly effective treatments, while carrying high upfront costs, can dramatically reduce these ongoing expenses while immeasurably improving patient quality of life. Jill Vedder, chairwoman of EBRP, said, 'It's amazing to witness how far we've come. Epidermolysis Bullosa may be rare, but through the tireless work of our community, our message is reaching more people than ever. This is more than awareness; it's an urgent push to cure EB by 2030, and together, I know we can make it happen.' BEVERLY HILLS, CA - MARCH 04: Jill and Eddie Vedder Beverly Hills, California. (Photo by J. ...) Celebrity Advocacy's Growing Impact on Medical Research The Vedders' commitment to EB research reflects a broader trend of entertainment figures using their platforms for targeted medical advocacy. Unlike general health awareness campaigns, this focused approach allows celebrities to drive significant resources toward specific conditions that might otherwise struggle for attention. The musician's concerts and documentary represent what researchers call 'translational advocacy'—efforts that don't just raise awareness but directly fund the research needed to develop treatments. This model has proven particularly effective for rare diseases, where traditional pharmaceutical development models often fall short due to small patient populations. "We are thankful for the Vedders' commitment to this community, their platform has accelerated an innovative approach for medical research,' said Michael Hund, CEO of EB Research Partnership, 'Our hope is that our model for EB of novel technology solutions, inspiring collaboration across the medical community, and a pioneering venture philanthropy investment strategy, can lead to not only treatments and cures for EB, but also provide a road map for the greater rare disease population." Looking Toward a Future Without EB The convergence of scientific breakthrough and celebrity advocacy suggests that EB may soon join the ranks of genetic diseases that have been transformed from fatal to manageable or even curable. Recent breakthroughs in gene therapy continue to transform the landscape of therapies for epidermolysis bullosa (EB), offering encouraging outcomes for patients suffering from this severe blistering skin disease. For families affected by EB, the message from the Vedders' advocacy and recent scientific advances is clear: hope is not just possible—it's scientifically justified. The combination of approved therapies, promising clinical trials, and sustained advocacy efforts suggests that the 'matter of time' Vedder references may be shorter than many dared hope. The Road Ahead As Matter of Time prepares for release, it will likely serve as both documentation of current progress and catalyst for future advances. The film promises to showcase the human faces behind the science, making the urgent need for continued research impossible to ignore. The story of EB treatment development demonstrates how breakthrough medical advances often require more than just scientific innovation—they need sustained advocacy, patient courage, and public support. The Vedders' commitment to this cause exemplifies how celebrity platforms, when used thoughtfully, can accelerate the translation of laboratory discoveries into real-world treatments. For the EB community, this moment represents unprecedented convergence of hope and possibility. Between approved gene therapies, promising research pipelines, and sustained advocacy efforts, the future for butterfly children looks brighter than ever before. As Vedder suggests, it truly may be just a matter of time.
Globe and Mail
22-05-2025
- Business
- Globe and Mail
Micro-Cap Biotech Skyrockets on FDA Pediatric Disease Nod
FDA approvals are often market-moving events, and today a micro-cap biotech company saw its shares surge after receiving Rare Pediatric Disease designation from the FDA. Relief Therapeutics Holding SA (OTCQB:RLFTF) (OTCQB:RLFTY) announced this morning that the U.S. FDA has granted Rare Pediatric Disease (RPD) designation to its drug candidate RLF-TD011 for the treatment of epidermolysis bullosa (EB), a rare genetic skin disorder. This follows a previous Orphan Drug Designation for the same condition. RLF-TD011 is a hypotonic acid-oxidizing solution containing hypochlorous acid, developed to offer antimicrobial and anti-inflammatory effects while promoting a healing wound environment. The company has reported encouraging clinical results, highlighting the drug's potential to improve EB wound care by modulating the wound microbiome and reducing harmful bacterial colonization. "The FDA's decision to grant Rare Pediatric Disease designation to RLF-TD011 underscores both the critical need for new options for patients living with EB and the potential of our investigational therapy," said Giorgio Reiner, chief scientific officer of Relief. "We look forward to continued engagement with the FDA and to sharing the next steps in our development plan following our upcoming pre-IND meeting." The FDA grants RPD designation to product candidates targeting serious or life-threatening diseases that primarily affect individuals aged 18 years or younger and impact fewer than 200,000 people in the U.S. Companies that receive marketing approval for an RPD-designated indication may be eligible-subject to certain conditions, including congressional reauthorization of the program for designations granted after December 20, 2024-to receive a Priority Review Voucher (PRV), which grants expedited FDA review for a future marketing application. These vouchers are transferable; in May 2025, a PRV awarded following the approval of a treatment for a rare form of EB was sold for $155 million. Shares of RLFTF are surging on the news, currently up 49.62% at $3.89 while shares of RLFTY trade up 40.34% at $4.07 in late-morning trading. Copyright © 2025 All rights reserved. Republication or redistribution of content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. View more of this article on About Media, Inc.: Founded in 1999, is one of North America's leading platforms for micro-cap insights. Catering to both Canadian and U.S. markets, we provide a wealth of resources and expert content designed for everyone—from beginner investors to seasoned traders. is rapidly gaining recognition as a leading authority in the micro-cap space, with our insightful content prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals. Want to showcase your company's story to a powerful network of investors? We can help you elevate your message and make a lasting impact. Contact us today. Contact: Media, Inc.
Yahoo
22-05-2025
- Business
- Yahoo
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
GENEVA, SWITZERLAND / / May 22, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to RLF-TD011 for the treatment of epidermolysis bullosa (EB), a rare genetic skin disorder characterized by fragile skin and chronic wounds. The FDA had previously granted Orphan Drug Designation to RLF-TD011 for the same indication. RLF-TD011 is a differentiated, hypotonic acid-oxidizing solution formulated with hypochlorous acid, designed to deliver potent antimicrobial and anti-inflammatory activity while creating a wound microenvironment conducive to healing. The Company previously reported promising clinical findings supporting RLF-TD011's potential to meaningfully advance EB wound care by modulating the wound microbiome and reducing pathogenic colonization without disrupting beneficial bacteria. "The FDA's decision to grant Rare Pediatric Disease designation to RLF-TD011 underscores both the critical need for new options for patients living with EB and the potential of our investigational therapy," said Giorgio Reiner, chief scientific officer of Relief. "We look forward to continued engagement with the FDA and to sharing the next steps in our development plan following our upcoming pre-IND meeting." The FDA grants RPD designation to product candidates targeting serious or life-threatening diseases that primarily affect individuals aged 18 years or younger and impact fewer than 200,000 people in the U.S. Companies that receive marketing approval for an RPD-designated indication may be eligible-subject to certain conditions, including congressional reauthorization of the program for designations granted after December 20, 2024-to receive a Priority Review Voucher (PRV), which grants expedited FDA review for a future marketing application. These vouchers are transferable; in May 2025, a PRV awarded following the approval of a treatment for a rare form of EB was sold for $155 million. ABOUT EPIDERMOLYSIS BULLOSAEpidermolysis bullosa (EB) is a group of rare, inherited connective tissue disorders characterized by extreme skin fragility, leading to blistering and wounds from minor friction or injury. In severe cases, blisters can develop into chronic wounds or form in internal organs such as the mouth or esophagus, leading to painful wounds, recurrent infections, and a deeply impacted quality of life. EB is classified into several major inherited subtypes, each defined by the depth of blister formation within the skin's layers: epidermolysis bullosa simplex (EBS), dystrophic epidermolysis bullosa (DEB), junctional epidermolysis bullosa (JEB) and Kindler syndrome (KS). Treatment is intensive and includes wound care, infection prevention, and pain management. Approximately 500,000 individuals worldwide are affected by EB. ABOUT RLF-TD011RLF-TD011 is a highly pure, stabilized hypochlorous acid solution developed using Relief's proprietary TEHCLO™ technology. With strong antimicrobial properties, RLF-TD011 is a sprayable, self-administered solution for targeted wound application while avoiding skin contact and cross-contamination. Relief's acid-oxidizing solution has previously demonstrated efficacy in accelerating wound closure and reducing infections in certain clinical trials on non-EB wounds. In an investigator-initiated trial (NCT05533866), RLF-TD011 has also shown promising results in infection control and wound healing in EB patients with the most severe forms of the disease. RLF-TD011 aims to address unmet needs in EB care by efficiently controlling infection and inflammation while reducing antibiotic use and easing the intensive, time-consuming wound care routine required by current treatments. The U.S. Food and Drug Administration has granted RLF-TD011 both Orphan Drug and Rare Pediatric Disease designations for EB, and Relief plans to seek Qualified Infectious Disease Product (QIDP) designation for extended market exclusivity. ABOUT RELIEFRelief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit CONTACTRELIEF THERAPEUTICS Holding SAJeremy MeinenChief Financial Officercontact@ DISCLAIMERThis press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise. SOURCE: Relief Therapeutics Holding SA View the original press release on ACCESS Newswire Sign in to access your portfolio
Associated Press
22-05-2025
- Business
- Associated Press
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
GENEVA, SWITZERLAND / ACCESS Newswire / May 22, 2025 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to RLF-TD011 for the treatment of epidermolysis bullosa (EB), a rare genetic skin disorder characterized by fragile skin and chronic wounds. The FDA had previously granted Orphan Drug Designation to RLF-TD011 for the same indication. RLF-TD011 is a differentiated, hypotonic acid-oxidizing solution formulated with hypochlorous acid, designed to deliver potent antimicrobial and anti-inflammatory activity while creating a wound microenvironment conducive to healing. The Company previously reported promising clinical findings supporting RLF-TD011's potential to meaningfully advance EB wound care by modulating the wound microbiome and reducing pathogenic colonization without disrupting beneficial bacteria. 'The FDA's decision to grant Rare Pediatric Disease designation to RLF-TD011 underscores both the critical need for new options for patients living with EB and the potential of our investigational therapy,' said Giorgio Reiner, chief scientific officer of Relief. 'We look forward to continued engagement with the FDA and to sharing the next steps in our development plan following our upcoming pre-IND meeting.' The FDA grants RPD designation to product candidates targeting serious or life-threatening diseases that primarily affect individuals aged 18 years or younger and impact fewer than 200,000 people in the U.S. Companies that receive marketing approval for an RPD-designated indication may be eligible-subject to certain conditions, including congressional reauthorization of the program for designations granted after December 20, 2024-to receive a Priority Review Voucher (PRV), which grants expedited FDA review for a future marketing application. These vouchers are transferable; in May 2025, a PRV awarded following the approval of a treatment for a rare form of EB was sold for $155 million. ABOUT EPIDERMOLYSIS BULLOSA Epidermolysis bullosa (EB) is a group of rare, inherited connective tissue disorders characterized by extreme skin fragility, leading to blistering and wounds from minor friction or injury. In severe cases, blisters can develop into chronic wounds or form in internal organs such as the mouth or esophagus, leading to painful wounds, recurrent infections, and a deeply impacted quality of life. EB is classified into several major inherited subtypes, each defined by the depth of blister formation within the skin's layers: epidermolysis bullosa simplex (EBS), dystrophic epidermolysis bullosa (DEB), junctional epidermolysis bullosa (JEB) and Kindler syndrome (KS). Treatment is intensive and includes wound care, infection prevention, and pain management. Approximately 500,000 individuals worldwide are affected by EB. ABOUT RLF-TD011 RLF-TD011 is a highly pure, stabilized hypochlorous acid solution developed using Relief's proprietary TEHCLO™ technology. With strong antimicrobial properties, RLF-TD011 is a sprayable, self-administered solution for targeted wound application while avoiding skin contact and cross-contamination. Relief's acid-oxidizing solution has previously demonstrated efficacy in accelerating wound closure and reducing infections in certain clinical trials on non-EB wounds. In an investigator-initiated trial (NCT05533866), RLF-TD011 has also shown promising results in infection control and wound healing in EB patients with the most severe forms of the disease. RLF-TD011 aims to address unmet needs in EB care by efficiently controlling infection and inflammation while reducing antibiotic use and easing the intensive, time-consuming wound care routine required by current treatments. The U.S. Food and Drug Administration has granted RLF-TD011 both Orphan Drug and Rare Pediatric Disease designations for EB, and Relief plans to seek Qualified Infectious Disease Product (QIDP) designation for extended market exclusivity. ABOUT RELIEF Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit CONTACT RELIEF THERAPEUTICS Holding SA Jeremy Meinen Chief Financial Officer [email protected] DISCLAIMER This press release contains forward-looking statements, which may be identified by words such as 'believe,' 'assume,' 'expect,' 'intend,' 'may,' 'could,' 'will,' or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise. SOURCE: Relief Therapeutics Holding SA press release
Yahoo
22-05-2025
- Business
- Yahoo
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
GENEVA, SWITZERLAND / / May 22, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to RLF-TD011 for the treatment of epidermolysis bullosa (EB), a rare genetic skin disorder characterized by fragile skin and chronic wounds. The FDA had previously granted Orphan Drug Designation to RLF-TD011 for the same indication. RLF-TD011 is a differentiated, hypotonic acid-oxidizing solution formulated with hypochlorous acid, designed to deliver potent antimicrobial and anti-inflammatory activity while creating a wound microenvironment conducive to healing. The Company previously reported promising clinical findings supporting RLF-TD011's potential to meaningfully advance EB wound care by modulating the wound microbiome and reducing pathogenic colonization without disrupting beneficial bacteria. "The FDA's decision to grant Rare Pediatric Disease designation to RLF-TD011 underscores both the critical need for new options for patients living with EB and the potential of our investigational therapy," said Giorgio Reiner, chief scientific officer of Relief. "We look forward to continued engagement with the FDA and to sharing the next steps in our development plan following our upcoming pre-IND meeting." The FDA grants RPD designation to product candidates targeting serious or life-threatening diseases that primarily affect individuals aged 18 years or younger and impact fewer than 200,000 people in the U.S. Companies that receive marketing approval for an RPD-designated indication may be eligible-subject to certain conditions, including congressional reauthorization of the program for designations granted after December 20, 2024-to receive a Priority Review Voucher (PRV), which grants expedited FDA review for a future marketing application. These vouchers are transferable; in May 2025, a PRV awarded following the approval of a treatment for a rare form of EB was sold for $155 million. ABOUT EPIDERMOLYSIS BULLOSAEpidermolysis bullosa (EB) is a group of rare, inherited connective tissue disorders characterized by extreme skin fragility, leading to blistering and wounds from minor friction or injury. In severe cases, blisters can develop into chronic wounds or form in internal organs such as the mouth or esophagus, leading to painful wounds, recurrent infections, and a deeply impacted quality of life. EB is classified into several major inherited subtypes, each defined by the depth of blister formation within the skin's layers: epidermolysis bullosa simplex (EBS), dystrophic epidermolysis bullosa (DEB), junctional epidermolysis bullosa (JEB) and Kindler syndrome (KS). Treatment is intensive and includes wound care, infection prevention, and pain management. Approximately 500,000 individuals worldwide are affected by EB. ABOUT RLF-TD011RLF-TD011 is a highly pure, stabilized hypochlorous acid solution developed using Relief's proprietary TEHCLO™ technology. With strong antimicrobial properties, RLF-TD011 is a sprayable, self-administered solution for targeted wound application while avoiding skin contact and cross-contamination. Relief's acid-oxidizing solution has previously demonstrated efficacy in accelerating wound closure and reducing infections in certain clinical trials on non-EB wounds. In an investigator-initiated trial (NCT05533866), RLF-TD011 has also shown promising results in infection control and wound healing in EB patients with the most severe forms of the disease. RLF-TD011 aims to address unmet needs in EB care by efficiently controlling infection and inflammation while reducing antibiotic use and easing the intensive, time-consuming wound care routine required by current treatments. The U.S. Food and Drug Administration has granted RLF-TD011 both Orphan Drug and Rare Pediatric Disease designations for EB, and Relief plans to seek Qualified Infectious Disease Product (QIDP) designation for extended market exclusivity. ABOUT RELIEFRelief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit CONTACTRELIEF THERAPEUTICS Holding SAJeremy MeinenChief Financial Officercontact@ DISCLAIMERThis press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise. SOURCE: Relief Therapeutics Holding SA View the original press release on ACCESS Newswire
